Lista de obras - Klazien Matter-Walstra - Dominio Público Uruguay

A Cost-Effectiveness Analysis of Nivolumab versus Docetaxel for Advanced Nonsquamous NSCLC Including PD-L1 Testing.

artículo científico publicado en 2016

A cost-effectiveness analysis of trametinib plus dabrafenib as first-line therapy for metastatic BRAF V600-mutated melanoma in the Swiss setting.

artículo científico publicado en 2015

Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer: a cost-utility analysis

scientific article published on 13 September 2010

Atypical cells in effusions: diagnostic value of cell image analysis combined with immunocytochemistry

scientific article published on 01 November 1996

Bevacizumab Continuation Versus Treatment Holidays After First-Line Chemotherapy With Bevacizumab in Patients With Metastatic Colorectal Cancer: A Health Economic Analysis of a Randomized Phase 3 Trial (SAKK 41/06)

artículo científico publicado en 2016

Bevacizumab in combination with paclitaxel for HER-2 negative metastatic breast cancer: an economic evaluation

artículo científico publicado en 2009

Cancer-related therapies at the end of life in hospitalized cancer patients from four Swiss cantons: SAKK 89/09.

artículo científico publicado en 2014

Cost Comparison Among First Line Monoclonal Antibodies-Based Oncology Treatment Protocols

scientific article published on 26 October 2014

Cost-effectiveness of maintenance pemetrexed in patients with advanced nonsquamous-cell lung cancer from the perspective of the Swiss health care system

scientific article published on 22 October 2011

Cost-effectiveness of palbociclib plus letrozole versus letrozole alone as a first-line treatment in women with oestrogen receptor-positive, HER2-negative, advanced breast cancer. Revised results for the Swiss health care setting

artículo científico publicado en 2017

Costs differences among monoclonal antibodies-based first-line oncology cancer protocols for breast cancer, colorectal carcinoma and non-Hodgkin's lymphoma

artículo científico publicado en 2014

Days spent in acute care hospitals at the end of life of cancer patients in four Swiss cantons: a retrospective database study (SAKK 89/09).

artículo científico publicado en 2016

Delivery of health care at the end of life in cancer patients of four swiss cantons: a retrospective database study (SAKK 89/09).

artículo científico publicado en 2014

End-of-life costs of medical care for advanced stage cancer patients.

artículo científico publicado en 2015

Is the EQ-5D suitable for use in oncology? An overview of the literature and recent developments.

artículo científico publicado en 2016

Off-label use of anticancer drugs in eastern Switzerland: a population-based prospective cohort study

artículo científico

Palbociclib as a first-line treatment in oestrogen receptor-positive, HER2-negative, advanced breast cancer not cost-effective with current pricing: a health economic analysis of the Swiss Group for Clinical Cancer Research (SAKK).

artículo científico publicado en 2016

Patient-based evaluations of primary care for cardiovascular diseases: a comparison between conventional and complementary medicine

artículo científico publicado en 2008

SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase I

scientific article published on 10 October 2016

Satisfaction with primary health care in patients with upper respiratory tract infection: a three-level approach.

artículo científico publicado en 2007

Seasonal variation in orthopedic health services utilization in Switzerland: the impact of winter sport tourism

artículo científico publicado en 2006

Trastuzumab beyond progression: a cost-utility analysis.

artículo científico publicado en 2010

Treatment specific utility-weightings are needed for cost-utility analysis in metastatic melanoma: reply from the authors

artículo científico publicado en 2016

Using the EuroQol EQ-5D in Swiss cancer patients, which value set should be applied?

artículo científico publicado en 2014

Lista de obras de Klazien Matter-Walstra

A Cost-Effectiveness Analysis of Nivolumab versus Docetaxel for Advanced Nonsquamous NSCLC Including PD-L1 Testing.

A cost-effectiveness analysis of trametinib plus dabrafenib as first-line therapy for metastatic BRAF V600-mutated melanoma in the Swiss setting.

Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer: a cost-utility analysis

Atypical cells in effusions: diagnostic value of cell image analysis combined with immunocytochemistry

Bevacizumab Continuation Versus Treatment Holidays After First-Line Chemotherapy With Bevacizumab in Patients With Metastatic Colorectal Cancer: A Health Economic Analysis of a Randomized Phase 3 Trial (SAKK 41/06)

Bevacizumab in combination with paclitaxel for HER-2 negative metastatic breast cancer: an economic evaluation

Cancer-related therapies at the end of life in hospitalized cancer patients from four Swiss cantons: SAKK 89/09.

Cost Comparison Among First Line Monoclonal Antibodies-Based Oncology Treatment Protocols

Cost-effectiveness of maintenance pemetrexed in patients with advanced nonsquamous-cell lung cancer from the perspective of the Swiss health care system

Cost-effectiveness of palbociclib plus letrozole versus letrozole alone as a first-line treatment in women with oestrogen receptor-positive, HER2-negative, advanced breast cancer. Revised results for the Swiss health care setting

Costs differences among monoclonal antibodies-based first-line oncology cancer protocols for breast cancer, colorectal carcinoma and non-Hodgkin's lymphoma

Days spent in acute care hospitals at the end of life of cancer patients in four Swiss cantons: a retrospective database study (SAKK 89/09).

Delivery of health care at the end of life in cancer patients of four swiss cantons: a retrospective database study (SAKK 89/09).

End-of-life costs of medical care for advanced stage cancer patients.

Is the EQ-5D suitable for use in oncology? An overview of the literature and recent developments.

Off-label use of anticancer drugs in eastern Switzerland: a population-based prospective cohort study

Palbociclib as a first-line treatment in oestrogen receptor-positive, HER2-negative, advanced breast cancer not cost-effective with current pricing: a health economic analysis of the Swiss Group for Clinical Cancer Research (SAKK).

Patient-based evaluations of primary care for cardiovascular diseases: a comparison between conventional and complementary medicine

SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase I

Satisfaction with primary health care in patients with upper respiratory tract infection: a three-level approach.

Seasonal variation in orthopedic health services utilization in Switzerland: the impact of winter sport tourism

Trastuzumab beyond progression: a cost-utility analysis.

Treatment specific utility-weightings are needed for cost-utility analysis in metastatic melanoma: reply from the authors

Using the EuroQol EQ-5D in Swiss cancer patients, which value set should be applied?